Zura Bio Limited (94E.F)

EUR 1.06

(6.0%)

Market Cap (In EUR)

75.07 Million

Revenue (In EUR)

-

Net Income (In EUR)

-60.36 Million

Avg. Volume

28.00

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.73-5.5
PE
-2.0
EPS
-0.53
Beta Value
0.135
ISIN
KYG9TY5A1016
CUSIP
-
CIK
-
Shares
70827528.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert Lisicki
Employee Count
-
Website
https://zurabio.com
Ipo Date
2023-03-21
Details
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.